Medical and Biological Laboratories Co., Ltd. (MBL) announced that "MEBRIGHTTM SARS-CoV-2 Kit" to be used for real-time one-step PCR assay was approved with marketing authorization of Pharmaceuticals and Medical Devices Act (PMDA) in Japan for the detection of novel coronavirus "SARS-CoV-2". In addition, the release date will be 2020/5/25 after it is covered by medical insurance of Japan. This kit was developed using a one-step real-time PCR assay platform described in the Manual for the Detection of Pathogen 2019-nCoV" by National Institute of Infectious Diseases (NIID) and yields comparable assay performance through a considerably simpler procedure. As an improved version of NIID method, which two target genes of novel coronavirus are interpreted in different wells, this kit uses a single-well dual-target assay. Furthermore, internal control is implemented to check if the PCR is working properly. In consequence of these improvements, both operability and performance are enhanced.